Mirum Pharmaceuticals: Strategic Moves Fuel 2026 Growth Ambitions

Mirum Pharmaceuticals has opened 2026 with a series of strategic initiatives designed to solidify its position in the rare disease sector. The biopharmaceutical firm is combining regulatory progress, a key acquisition, and robust financial targets to chart an aggressive growth path. The central question for investors is whether its clinical pipeline can deliver on these ambitious commercial expectations.

The company is building on a strong financial foundation from 2025. Preliminary net product revenue reached approximately $520 million, surpassing initial projections. For the current fiscal year, management has set a more ambitious target, guiding for revenue to climb to between $630 million and $650 million. This forecast represents a potential increase of up to 25% year-over-year.

Portfolio Expansion Through Acquisition and Approval

A significant step in Mirum's strategy was the completion of its acquisition of Bluejay Therapeutics in late January. This deal brought the drug candidate Brelovitug into its pipeline, targeting chronic Hepatitis Delta virus (HDV). HDV is considered the most severe form of viral hepatitis, and the program has already been granted "Breakthrough Therapy" designation by the U.S. FDA. Initial pivotal study data are anticipated in the second half of 2026, potentially paving the way for a market launch in 2027.

Should investors sell immediately? Or is it worth buying Mirum Pharmaceuticals?

In a separate regulatory win, Health Canada recently approved LIVMARLI. The oral medication is now authorized for treating cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome. This decision significantly broadens the drug's global commercial footprint.

Clinical Milestones on the Horizon

The coming months will be critical for validating the company's long-term growth narrative. Several key clinical readouts are scheduled:
* Q2 2026: Results from the Phase 2b study of Volixibat for primary sclerosing cholangitis (PSC) are expected.
* Before year-end 2026: The company plans to present topline data from the Phase 3 EXPAND study for LIVMARLI.

The outcomes of these trials will be instrumental in determining if Mirum can sustain its current rapid expansion trajectory and meet its elevated revenue goals.